Market Intelligence, Clinical Progress, and High-Purity Reagents for Fc Receptor Characterization and Targeted Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD64/FCGR1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCGR1A/CD64 ECD-Fc / Monomeric His-tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View FCGR1A Products |
| Gene Delivery | FCGR1A/CD64 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (Flow Cytometry/ADCP assays). |
View FCGR1A Products |
| Benchmark Ab | Anti-FCGR1A Recombinant Antibody Recombinant positive control matching clinical benchmark sequences. |
View FCGR1A Products |
| Validator | FCGR1A/CD64 siRNA Set For target knockdown verification in primary macrophages. |
View FCGR1A Products |
| Related Target A | FCGR3A/CD16a Low-affinity activating Fc receptor; crucial for off-target/selectivity profiling panels. |
View FCGR3A Products |
| Related Target B | FCGR2A/CD32a Low-affinity activating Fc receptor; essential for comprehensive FcR profile validation. |
View FCGR2A Products |
| Related Target C | FCGRT/FcRn Neonatal Fc receptor; required to evaluate antibody half-life and recycling kinetics. |
View FCGRT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-Affinity Monomeric Binding Calibration | HEK293-expressed monomeric FCGR1A prevents artificial avidity effects in SPR/BLI assays. |
| Glycosylation-Sensitive Interaction Mapping | Strictly controlled mammalian expression ensures native post-translational modifications. |
| Lack of Reliable Reference Controls | Sequence-verified biosimilar antibodies included to establish assay baselines. |
| Target Specificity Verification | Sequence-verified siRNA panels enable robust loss-of-function validation. |
Live CD64/FCGR1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting and profiling of CD64 (FCGR1A) are expanding beyond traditional immunology diagnostics. As the sole high-affinity receptor for monomeric IgG, CD64 plays a pivotal role in mediating antibody-dependent cellular phagocytosis (ADCP) by macrophages. Current drug discovery pipelines are leveraging CD64 in two major ways: first, as a target for immunotoxins and bispecific antibodies aimed at depleting inflammatory macrophages or treating acute myeloid leukemia (AML); second, as an indispensable target in the safety and efficacy profiling of all therapeutic monoclonal antibodies, bispecifics, and ADCs to evaluate Fc-mediated effector functions and potential toxicity.
The next wave of R&D focuses on optimizing the Fc-region of therapeutic antibodies to either enhance or silence CD64 binding, requiring highly precise, reproducible in vitro binding assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies (e.g., CD64 x Tumor Antigen) | Academic Institutes, Biotech Outfits | Oncology, Autoimmune Diseases | Dual-targeting validation requiring high-purity monomeric CD64 proteins. |
| Fc-Engineered mAbs (ADCC/ADCP Enhanced) | Major Pharma, Biosimilar Developers | Solid Tumors, Hematologic Malignancies | SPR/BLI binding kinetic assays utilizing native glycosylated CD64. |
| Immunotoxins / ADCs | Clinical-stage Biotechs | Acute Myeloid Leukemia (AML), Chronic Inflammation | Lentivirus-mediated stable cell lines to validate CD64-targeted internalization. |